La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Cytosorbents Croissance future

Future contrôle des critères 2/6

Cytosorbents devrait augmenter ses bénéfices et ses revenus de 60.3% et de 21.1% par an respectivement, tandis que le BPA devrait croître de croître de 63.9% par an.

Informations clés

63.7%

Taux de croissance des bénéfices

67.1%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.6%
Taux de croissance des recettes	20.6%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	04 Sep 2024

Mises à jour récentes de la croissance future

Recent updates

Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

Jul 04

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Mar 16

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Jan 06

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Nov 10

Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Jul 13

CytoSorbents stock rises on US DoD contract to develop device for universal plasma

Sep 09

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Sep 02

CytoSorbents gets reimbursement for CytoSorb in Turkey

Aug 23

CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system

Aug 17

Cytosorbents GAAP EPS of -$0.25 misses by $0.13, revenue of $8.5M misses by $1.06M

Aug 02

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:CTSO - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	55	-3	-12	-11	3
12/31/2025	46	-9	-21	-20	4
12/31/2024	40	-17	-26	-26	4
6/30/2024	37	-26	-22	-21	N/A
3/31/2024	37	-28	-24	-23	N/A
12/31/2023	36	-29	-23	-22	N/A
9/30/2023	37	-23	-22	-21	N/A
6/30/2023	36	-26	-24	-22	N/A
3/31/2023	35	-31	-30	-23	N/A
12/31/2022	35	-33	-35	-28	N/A
9/30/2022	36	-41	-36	-28	N/A
6/30/2022	38	-36	-34	-26	N/A
3/31/2022	41	-29	-24	-20	N/A
12/31/2021	43	-25	-18	-14	N/A
9/30/2021	44	-16	-12	-10	N/A
6/30/2021	45	-10	-11	-9	N/A
3/31/2021	43	-9	-7	-5	N/A
12/31/2020	41	-8	-7	-6	N/A
9/30/2020	36	-11	-10	-9	N/A
6/30/2020	32	-17	-12	-11	N/A
3/31/2020	28	-18	-17	-16	N/A
12/31/2019	25	-19	-18	-17	N/A
9/30/2019	24	-21	-17	-15	N/A
6/30/2019	23	-17	-14	-13	N/A
3/31/2019	23	-19	-14	-13	N/A
12/31/2018	23	-17	-12	-11	N/A
9/30/2018	21	-15	-10	-9	N/A
6/30/2018	19	-14	-10	-8	N/A
3/31/2018	17	-10	N/A	-7	N/A
12/31/2017	15	-9	N/A	-6	N/A
9/30/2017	14	-11	N/A	-7	N/A
6/30/2017	12	-10	N/A	-7	N/A
3/31/2017	11	-11	N/A	-7	N/A
12/31/2016	10	-12	N/A	-7	N/A
9/30/2016	8	-9	N/A	-8	N/A
6/30/2016	7	-10	N/A	-8	N/A
3/31/2016	6	-5	N/A	-8	N/A
12/31/2015	5	-9	N/A	-9	N/A
9/30/2015	4	-17	N/A	-9	N/A
6/30/2015	4	-17	N/A	-9	N/A
3/31/2015	4	-21	N/A	-8	N/A
12/31/2014	4	-19	N/A	-6	N/A
9/30/2014	4	-9	N/A	-5	N/A
6/30/2014	4	-8	N/A	-4	N/A
3/31/2014	3	-7	N/A	-3	N/A
12/31/2013	2	-7	N/A	-3	N/A
9/30/2013	2	-7	N/A	-3	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CTSO devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: CTSO devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: CTSO devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CTSO ( 21.1% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CTSO ( 21.1% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CTSO devrait être élevé dans 3 ans

Cytosorbents Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates upgraded to US$0.31 loss

No longer forecast to breakeven

No longer forecast to breakeven

Price target decreased by 20% to US$4.50

Price target decreased by 10.0% to US$5.40

Consensus EPS estimates fall by 20%

Recent updates

Consensus EPS estimates upgraded to US$0.31 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cytosorbents Corporation Announces Chief Financial Officer Changes

Cytosorbents Corporation to Report Q2, 2024 Results on Aug 13, 2024

CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement

Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

CytoSorbents Corporation Announces Regulatory Approval of CytoSorb® in Taiwan

Cytosorbents Corporation Announces the Launch and Immediate Availability of the PuriFi Blood Pump in the European Union

Cytosorbents Corporation Receives Notice Regarding Nasdaq Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.64 loss per share (vs US$0.75 loss in FY 2022)

No longer forecast to breakeven

Cytosorbents Corporation to Report Q1, 2024 Results on May 09, 2024

Cytosorbents Corporation, Annual General Meeting, Jun 06, 2024

No longer forecast to breakeven

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Cytosorbents Corporation to Report Fiscal Year 2023 Results on Mar 14, 2024

Cytosorbents Corporation Reports Excellent Outcomes from A Groundbreaking Randomized Controlled Trial (Rct) Using Cytosorb® Blood Purification During Heart Transplant, Recently Published in the European Society of Cardiology Journal, Esc Heart Failure

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Price target decreased by 20% to US$4.50

New minor risk - Profitability

Price target decreased by 10.0% to US$5.40

Cytosorbents Corporation Provides Update on the Star-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

New minor risk - Shareholder dilution

Cytosorbents Corporation has completed a Follow-on Equity Offering in the amount of $10.28501 million.

Cytosorbents Corporation announced that it expects to receive $10.28501 million in funding

New minor risk - Share price stability

Consensus EPS estimates fall by 20%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Cytosorbents Corporation Announces Appointment of Kathleen Bloch as Full-Time CFO

Cytosorbents Corporation Announces Resignation of Alexander D’Amico as Chief Financial Officer, Effective August 28, 2023

CytoSorbents Corporation Completes U.S. and Canadian Star-T Pivotal Trial

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Cytosorbents Corporation to Report Q2, 2023 Results on Aug 01, 2023

CytoSorbents Corporation Appoints Alexander D'Amico as Chief Financial Officer

Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

New minor risk - Share price stability

CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Consensus EPS estimates fall by 25%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO & Director exercised options to buy US$97k worth of stock.

Consensus EPS estimates fall by 34%

Full year 2022 earnings released: US$0.75 loss per share (vs US$0.57 loss in FY 2021)

Forecast breakeven date pushed back to 2025

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Cytosorbents Corporation to Report Q4, 2022 Results on Mar 09, 2023

CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial

Cytosorbents Corporation Appoints Irina B. Kulinets as Senior Vice President of Global Regulatory Affairs

Cytosorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal Star-T Trial as Planned Without Modifications

Consensus EPS estimates fall by 18%

Insufficient new directors

Cytosorbents Announces Pivotal Star-T Trial Reaches First Milestone with 40 Patients Enrolled

Consensus EPS estimates fall by 18%

Consensus EPS estimates fall by 18%

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.15 loss in 3Q 2021)

Price target decreased to US$6.67

CytoSorbents Corporation Announces Presentation of Final Key Results from the U.S. Multicenter Cytosorb Therapy

Cytosorbents Corporation to Report Q3, 2022 Results on Nov 03, 2022

CytoSorbents Corporation Announces Retirement of Kathleen P. Bloch, Chief Financial Officer

CytoSorbents secures $4.3M contract by U.S. Department of Defense

CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey

CEO & Director recently bought US$60k worth of stock

U.S. Army Medical Research Acquisition Activity Awards CytoSorbents an Approximately $2.0 Million Contract to Support Hemodefend-Bga(Tm) Development for Life-Saving Universal Plasma

CytoSorbents stock rises on US DoD contract to develop device for universal plasma

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Cytosorbents Corporation Announces Turkish Ministry of Health Grants National Reimbursement to CytoSorb(R)